Dr. Kris Discusses the Pemetrexed Trial Results

Mark G. Kris, MD, the chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the pemetrexed clinical trial results.

Dr. Kris says by continuing pemetrexed in patients who began their treatments with pemetrexed, the patients had a longer disease-free survival. Generally disease-free survival translates into life where cancer does not disrupt it. That improvement was achieved just by continuing a medicine that the patients were already on. Survival data is not out yet, and it's something that will be looked for, but regardless, the time free of cancer is clearly improved.